drugset / Trial / NCT02631109
L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis
NaSingle-groupOpen-labelTreatment
Summary
This study aimed to investigate the efficacy and safety of Pegaspargase together with liposomal doxorubicin, etoposide and high dose methylprednisolone (L-DEP) as a salvage therapy for refractory Epstein Barr virus-induced hemophagocytic lymphohistiocytosis.
Timeline
- Start
- 2015-12
- Primary completion
- 2017-11
- Completion
- 2019-11
Publications
- Background Wang Y, Huang W, Hu L, Cen X, Li L, Wang J, Shen J, Wei N, Wang Z. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis. Blood. 2015 Nov 5;126(19):2186-92. doi: 10.1182/blood-2015-05-644914. Epub 2015 Aug 19.
- Wang J, Wang Y, Wu L, Zhang J, Lai W, Wang Z. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Hematol Oncol. 2016 Sep 9;9(1):84. doi: 10.1186/s13045-016-0317-7.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Doxorubicin | Other / unclassified | 25 mg/m2 | — |
| Background | Etoposide | Small molecule | 100 mg/m2 | — |
| Background | Methylprednisolone | Other / unclassified | 0.75 mg/kg | — |
| Background | Pegaspargase | Protein / enzyme biologic | 2000 unknown | — |